PPA
AUPH icon

Parametric Portfolio Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Parametric Portfolio Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$248K Sell
20,057
-4,747
-19% -$73.4K ﹤0.01% 3358
2021
Q4 		$567K Sell
24,804
-1,258
-5% -$29.8K ﹤0.01% 3022
2021
Q3 		$577K Sell
26,062
-6,734
-21% -$107K ﹤0.01% 3038
2021
Q2 		$425K Buy
32,796
+6,462
+25% +$82.3K ﹤0.01% 3148
2021
Q1 		$342K Buy
+26,334
New +$382K ﹤0.01% 3663

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Parametric Portfolio Associates's AUPH Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Aurinia Pharmaceuticals (AUPH) stake by 19% in Q1 2022, selling an estimated $73.4K and leaving 20,057 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

Parametric Portfolio Associates first reported a position in AUPH in Q1 2021 and has held it in 5 quarters since. The position peaked at $577K in Q3 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Parametric Portfolio Associates held 20,057 shares of Aurinia Pharmaceuticals worth $248K as of Q1 2022.
  • Parametric Portfolio Associates sold 4,747 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $73.4K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3358 holding.
  • Parametric Portfolio Associates first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
  • Parametric Portfolio Associates's Aurinia Pharmaceuticals position peaked at $577K in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.